tiprankstipranks
Advertisement
Advertisement

CRVO Stock Latest News

CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
RatingsCervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
6d ago
CRVO
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
PremiumRatings
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
6d ago
CRVO
CervoMed Highlights Q1 Results and Neflamapimod Progress
PremiumCompany Announcements
CervoMed Highlights Q1 Results and Neflamapimod Progress
6d ago
8K
CRVO
CervoMed price target lowered to $9 from $11 at Roth Capital
PremiumThe Fly
CervoMed price target lowered to $9 from $11 at Roth Capital
6d ago
CRVO
CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
8d ago
CRVO
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
PremiumRatingsNeflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
1M ago
CRVO
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
Premium
Company Announcements
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
1M ago
8K
CRVO
CervoMed presents neflamapimod MRI data
Premium
The Fly
CervoMed presents neflamapimod MRI data
1M ago
CRVO
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
PremiumCompany Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
2M ago
8K
CRVO
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
PremiumCompany Announcements
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
2M ago
8K
CRVO
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
PremiumCompany Announcements
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
2M ago
8K
CRVO
CervoMed’s neflamapimod shows efficacy in dementia with DLB
PremiumThe Fly
CervoMed’s neflamapimod shows efficacy in dementia with DLB
2M ago
CRVO
CervoMed price target lowered to $11 from $19 at Roth Capital
PremiumThe FlyCervoMed price target lowered to $11 from $19 at Roth Capital
2M ago
CRVO
CervoMed price target raised to $21 from $15 at Chardan
Premium
The Fly
CervoMed price target raised to $21 from $15 at Chardan
2M ago
CRVO
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
Premium
Company Announcements
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
2M ago
8K
CRVO
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
PremiumRatings
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
2M ago
CRVO
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
PremiumThe Fly
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
2M ago
CRVO
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
PremiumRatings
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
2M ago
CRVO
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
PremiumCompany Announcements
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
2M ago
CRVO
CervoMed announces presentations at AP/PD 2026 scientific conference
PremiumThe FlyCervoMed announces presentations at AP/PD 2026 scientific conference
2M ago
CRVO
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
Premium
Market News
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
3M ago
CRVO
TCRX
CervoMed Advances Neflamapimod With Phase 1 Completion
Premium
Company Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
3M ago
8K
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >